Resultados clínicos del uso de los nuevos antiagregantes en la vida real

Abstract

The increasing amount of real-world data available on the use of double antiplatelet therapy with new antiplatelet agents, including data from Spanish centers (e.g. the EPICOR, ARIAM and ACHILLES studies), appear to confirm the findings of large pivotal trials. Generally, use of these agents results in substantial clinical benefits, including fewer ischemic events and lower mortality, but there is usually an associated increase risk of hemorrhage. The uptake of these new antiplatelet agents continues to grow relative to that of clopidogrel-based double antiplatelet therapy. In addition, prolonged use of dual antiplatelet therapy is common practice in the real world, with substantial variations between countries. Therapeutic outcomes depend to a large extent on the risk profiles of, and the balance between ischemic and hemorrhagic risk in, patients included in individual case series.